Assess whether the primary endpoint will survive FDA scrutiny (05330c)

SITUATION A 505(b)(2) program relying on literature plus a bridging study cannot treat a site-change that invalidates stability claims as incidental context on complete-response-letter deficiency list. Clinical-development physician must close the primary endpoint will from that extract under Pharma & Life Sciences / Pharmacovigilance.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. A site-change that invalidates stability claims is noise around an already-controlled Pharmacovigilance process in a 505(b)(2) program relying on literature plus a bridging study, given complete-response-letter deficiency list. 2. A site-change that invalidates stability claims is the event in complete-response-letter deficiency list that forces Proceed under protocol for clinical-development physician under Pharma & Life Sciences. 3. Complete-response-letter deficiency list shows a one-file miss after a site-change that invalidates stability claims, not a Pharmacovigilance program failure. 4. Complete-response-letter deficiency list cannot decide the primary endpoint will yet after a site-change that invalidates stability claims; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 3. Check whether complete-response-letter deficiency list supports the labeled claim clinical-development physician would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a site-change that invalidates stability claims and write the one fact that would move the primary endpoint will for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in complete-response-letter deficiency list, then the action for clinical-development physician - Hypothesis scorecard against complete-response-letter deficiency list: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study